Incremental bioprocess improvements may be realized now through contiGuous bioprocessing, a next-generation approach to continuous bioprocessing enabled by MilliporeSigma’s BioContinuum™ Platform.
Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development HUB’s organoid offering complements company’s cell culture portfolio of media, ...
Young and emerging biotechnology companies rarely have enough background in biomanufacturing operations and clinical experience to get their products to the markets in an economic and efficient manner ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback